Oxygenta Pharmaceutical (524636) Q1 26/27 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter ended 30 June 2026 and scheduled the AGM for 21 August 2026 via video conferencing.

• Appointment of PCR & Associates as Cost Auditors for FY 2026-27 was approved.

• Reconstitution of the POSH Committee was completed.

Financial highlights

• Revenue from operations for Q1 FY 2026-27 was ₹3,699.69 lakhs, up from ₹1,513.47 lakhs in Q1 FY 2025-26.

• Total expenses for the quarter were ₹3,952.75 lakhs, compared to ₹2,343.99 lakhs in the same quarter last year.

• Loss before tax for the quarter was ₹250.73 lakhs, an improvement from a loss of ₹814.80 lakhs year-over-year.

• Basic and diluted EPS for the quarter were both (₹0.57), compared to (₹1.65) in Q1 FY 2025-26.

Outlook and guidance

• The company is actively working to complete identification of MSME creditors and has requested self-declarations from suppliers.